Skip to main
ANAB

AnaptysBio (ANAB) Stock Forecast & Price Target

AnaptysBio (ANAB) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 55%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

AnaptysBio is expected to generate significant revenue from successful clinical trials such as JEMPERLI and PREDOSTAR, potentially reaching over $390 million in projected annual royalties starting in 2029. With a current projected stock value of $93 per share, ANAB could see further growth due to positive sales expectations and the potential resolution of a dispute with GSK. Additionally, ANAB has promising potential treatments in development for EoE and celiac disease, supported by strong preclinical data and expected to reach a resolution in June 2027. Using risk-adjusted net present value analysis, the updated PT for ANAB is $95.

Bears say

AnaptysBio is heavily dependent on the success of its pipeline, which is still in early stages of development. The company's financials are also heavily reliant on milestone payments and royalties, which are not guaranteed. Competition in the target markets is fierce, with larger and more established players, making it difficult for AnaptysBio to gain significant market share.

AnaptysBio (ANAB) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 55% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AnaptysBio (ANAB) Forecast

Analysts have given AnaptysBio (ANAB) a Buy based on their latest research and market trends.

According to 11 analysts, AnaptysBio (ANAB) has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $76.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $76.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AnaptysBio (ANAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.